Literature DB >> 32180985

Tegafur/gimeracil/oteracil-induced eosinophilic pneumonia.

Toshiyuki Sumi1,2, Hisashi Nakata1, Yuji Mori1, Hiroki Takahashi2.   

Abstract

Clinicians should be aware that eosinophilic pneumonia is one of the types of drug-induced lung injury that can be caused by tegafur/gimeracil/oteracil (TS-1).
© 2020 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.

Entities:  

Keywords:  Drug‐induced pneumonia; TS‐1; eosinophilic pneumonia

Year:  2020        PMID: 32180985      PMCID: PMC7063347          DOI: 10.1002/rcr2.551

Source DB:  PubMed          Journal:  Respirol Case Rep        ISSN: 2051-3380


Clinical Image

A 66‐year‐old man was admitted to the hospital with persistent high fever. He had received treatment with tegafur/gimeracil/oteracil (TS‐1) for adenocarcinoma of the gastro‐oesophageal junction 30 days previously. Chest computed tomography revealed ground‐glass opacities in bilateral lung fields (Fig. 1). Eosinophil fraction in peripheral blood had increased to 12.4% and that in the bronchoalveolar lavage fluid to 77%. Transbronchial lung biopsy revealed eosinophil infiltration in the lung tissues (Fig. 2), which suggested drug‐induced pulmonary toxicity; a drug lymphocyte stimulation test was highly positive for TS‐1. He was diagnosed with TS‐1‐induced eosinophilic pneumonia. Discontinuation of TS‐1 and initiation of prednisolone (starting from 0.5 mg/kg) improved his clinical symptoms and imaging findings (Fig. 1). Prednisolone was tapered over six weeks without recurrence. TS‐1, an oral drug with minimal side effects, is indicated in various malignancies. Drug‐induced pulmonary toxicity due to TS‐1 occurs rarely and there are a few reports. The histopathological findings commonly reported in TS‐1‐induced lung injury include organizing pneumonitis and non‐specific interstitial pneumonia 1, 2. To our knowledge, drug‐induced eosinophilic pneumonia secondary to TS‐1 has not been reported previously. Clinicians should be aware that eosinophilic pneumonia is a type of drug‐induced lung injury that can be caused by TS‐1.
Figure 1

Chest computed tomography (CT) findings. Upper row is before the onset of symptoms, middle row is during presentation, and lower row is after 14 days of prednisolone therapy. Chest CT at onset revealed ground‐glass opacities in bilateral lung fields, which disappeared after prednisolone therapy.

Figure 2

Histopathological findings following transbronchial lung biopsy. Lung specimens revealed fibrous thickening of the alveolar septum and eosinophil infiltration with eosinophilic granules (haematoxylin and eosin staining, 40×).

Chest computed tomography (CT) findings. Upper row is before the onset of symptoms, middle row is during presentation, and lower row is after 14 days of prednisolone therapy. Chest CT at onset revealed ground‐glass opacities in bilateral lung fields, which disappeared after prednisolone therapy. Histopathological findings following transbronchial lung biopsy. Lung specimens revealed fibrous thickening of the alveolar septum and eosinophil infiltration with eosinophilic granules (haematoxylin and eosin staining, 40×).

Disclosure Statement

Appropriate written informed consent was obtained for publication of this case report and accompanying images.
  3 in total

1.  [A case of drug-induced interstitial pneumonia caused by TS-1].

Authors:  Jun Nohara; Tetsuo Noguchi; Yasuto Sakaguchi; Tomoya Kono; Yasuji Terada
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2008-03

2.  [The value of transbronchial lung biopsy findings in the diagnosis of a case of TS-1-induced pulmonary toxicity].

Authors:  Shunsuke Ito; Tomoyoshi Yamaguchi; Ryo Morisue; Yukari Ogaw; Kazuo Munakata; Yuh Fukuda
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2011-12

3.  Tegafur/gimeracil/oteracil-induced eosinophilic pneumonia.

Authors:  Toshiyuki Sumi; Hisashi Nakata; Yuji Mori; Hiroki Takahashi
Journal:  Respirol Case Rep       Date:  2020-03-10
  3 in total
  1 in total

1.  Tegafur/gimeracil/oteracil-induced eosinophilic pneumonia.

Authors:  Toshiyuki Sumi; Hisashi Nakata; Yuji Mori; Hiroki Takahashi
Journal:  Respirol Case Rep       Date:  2020-03-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.